Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for companion animals, today announced the voting results of its 2021 Annual Virtual-Only Meeting of Shareholders (the “Meeting”) held on July 30, 2021.
At the Meeting, the Company’s shareholders approved the items of business as follows:
Additional information regarding the voting on these matters will be filed separately by the Company on SEDAR (www.sedar.com) and EDGAR (www.sec.gov).
About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for dogs and cats by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio will include innovative diagnostics and medical devices that emphasize patient health and practice health. It is Zomedica’s mission to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.
Follow Zomedica
Investor Relations Contact:
PCG Advisory
Kirin Smith, President
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1 646.863.6519
| Last Trade: | US$0.07 |
| Daily Change: | -0.0003 -0.41 |
| Daily Volume: | 388,327 |
| Market Cap: | US$70.560M |
October 23, 2025 October 14, 2025 October 09, 2025 September 23, 2025 September 18, 2025 | |

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load